10:38 AM
 | 
Oct 19, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eisai, Purdue insomnia candidate meets in second Phase III

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) said lemborexant met the primary and secondary endpoints in the Phase III SUNRISE 2 trial to treat insomnia. The trial is the second Phase III trial of the dual orexin receptor antagonist to report positive data.

In March, the partners said lemborexant met the primary and secondary endpoints vs. both placebo and zolpidem ER in the...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >